Literature DB >> 2088205

A three-dimensional model to analyze drug-drug interactions.

M N Prichard1, C Shipman.   

Abstract

Nearly four generations of investigators have studied combined drug effects. Their methods of generating and analyzing data have changed dramatically over the years but the basic problem has not. This review examines the inherent difficulties in analyzing combined drug effects and evaluates modern methods of describing these interactions. Researchers have traditionally used two-dimensional (2-D) methods to approximate the actual three-dimensional (3-D) nature of drug interactions. We conclude that these 2-D methods are often inadequate when used to analyze synergistic and antagonistic drug interactions in antiviral and anticancer chemotherapy. We propose a direct and pragmatic 3-D approach to the problem, made possible by microcomputers and sophisticated graphics programs. This procedure directly elucidates the shape of the dose-response surface, identifies the regions of statistically significant synergy and antagonism, and quantitates these effects. It also greatly simplifies the problem since a 3-D surface presents complete drug interactions in a way that can be easily interpreted. We will show that understanding the shape of the resulting 3-D surface is essential to an understanding of complex drug interactions. This new method facilitates the rigorous analysis of drug-drug interactions and offers investigators powerful new tools to analyze combinations of antiviral and anticancer drugs.

Mesh:

Substances:

Year:  1990        PMID: 2088205     DOI: 10.1016/0166-3542(90)90001-n

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  249 in total

1.  UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Authors:  A Monks; E D Harris; A Vaigro-Wolff; C D Hose; J W Connelly; E A Sausville
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

2.  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Authors:  Tomokazu Yoshinaga; Masanori Kobayashi; Takahiro Seki; Shigeru Miki; Chiaki Wakasa-Morimoto; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

4.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 5.  A few specialized issues that should be focused on anti-HIV drug evaluation in vitro.

Authors:  Dao-min Zhuang; Jing-yun Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

6.  In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors:  Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

7.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  An enhanced chemopreventive effect of methyl donor S-adenosylmethionine in combination with 25-hydroxyvitamin D in blocking mammary tumor growth and metastasis.

Authors:  Niaz Mahmood; Ani Arakelian; William J Muller; Moshe Szyf; Shafaat A Rabbani
Journal:  Bone Res       Date:  2020-07-22       Impact factor: 13.567

9.  Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.

Authors:  Rana Abdelnabi; Daryl Staveness; Katherine E Near; Paul A Wender; Leen Delang; Johan Neyts; Pieter Leyssen
Journal:  Biochem Pharmacol       Date:  2016-09-21       Impact factor: 5.858

10.  Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Authors:  Nagraj Mani; Andrew G Cole; Janet R Phelps; Andrzej Ardzinski; Kyle D Cobarrubias; Andrea Cuconati; Bruce D Dorsey; Ellen Evangelista; Kristi Fan; Fang Guo; Haitao Guo; Ju-Tao Guo; Troy O Harasym; Salam Kadhim; Steven G Kultgen; Amy C H Lee; Alice H L Li; Quanxin Long; Sara A Majeski; Richeng Mao; Kevin D McClintock; Stephen P Reid; Rene Rijnbrand; Nicholas M Snead; Holly M Micolochick Steuer; Kim Stever; Sunny Tang; Xiaohe Wang; Qiong Zhao; Michael J Sofia
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.